Company intelligence / Profile preview

Visus Therapeutics

Seattle, Washington, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

BRIMOCHOL™ (combining carbachol and brimonidine tartrate) demonstrated significant, durable improvement in near visual acuity in clinical studies for presbyopia, with a strong safety profile. The company expanded its pipeline through licenses and preclinical assets for glaucoma and AMD. Topline Phase 3 data for BRIMOCHOL™ were positive, and the company developed additional programs targeting front and back-of-the-eye diseases prior to merging with Tenpoint Therapeutics[1][2][4][5].

Therapeutic areas: Ophthalmology
Modalities: Small moleculeBiologicDeviceDrug delivery technology
Industry: Biotech

Partnerships

Cella Therapeutics (drug pipeline licensing for glaucoma and AMD)[4]DelSiTech Ltd (sustained-release drug delivery technology)[4]

Beyond the preview

Go deeper on Visus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visus Therapeutics.

Explore the full profile